Navigation Links
China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
Date:11/23/2007

n November 5, 2007, the Company entered into a new drug development contract with a third party. Pursuant to the contract, the Developer will transfer a drug patent to the Company, and also is responsible for obtaining the New Drug Certificate and the Drug Manufacturing Approval from the PRC Drug Administration Authority no later than July 1, 2009. In exchange, the Company will pay up to RMB12 million (approximately $1.6 million) to the Developer. Of the total $1.6 million, approximately $933,800 and $266,800 will need to be paid before December 31, 2007 and February 25, 2008, respectively, and the final payment ranging from $0 to $400,200, depending on the date of the Manufacturing Approval, needs to be paid no later than 10 days after the grant date of the Manufacturing Approval. Further, the two parties agreed that the Company will pay sales commission to the Developer based on the sales volume of the contracted new drug during a 10 year period after this drug is put into production. If the PRC Drug Administration Authority denies the application of the Drug Manufacturing, all payments made by the Company would be fully returned to the Company by the Developer.

Ms. Zhang Jian, continued, ''We believe that many of the distractions of the failed acquisition of Enshi are behind us. This has taken considerable management time and money away from our primary focus of building a strong pharmaceutical company in China. We now have the conditional conversion of $12.5 million of debt to equity, and believe that we will dramatically improve our cash position and have a one-time gain to income when we prevail in our Enshi litigation. We are happy to be working on new drug launches, which include an exciting new drug development agreement. We look forward to updating shareholder on these new products that we are working on to ensure our continued organic growth, as well as other potential accretive acquisition opportunities to increase our earnings and have a profitab
'/>"/>

SOURCE China Biopharmaceuticals Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... that use light, rather than electricity, to move ... energy efficiency is a growing concern as chips, ... components of optical circuits light emitters, modulators, ... build. One promising light source for optical chips ... properties when deposited as a single, atom-thick layer. ...
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... in medical technology, development of emerging drug systems and ... PBIO), Benton, Dickinson and Company (NYSE: BDX ... ), Regado Biosciences Inc. (NASDAQ: RGDO ), ... Hologic Inc. (NASDAQ: HOLX) Pressure BioSciences, Inc. ...
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... VANCOUVER , July 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ... quarter ended June 30, 2010 . , ... "We are pleased to report continued quarter over quarter ... Products," said Dr. William Hunter , President and CEO of Angiotech. ...
... lend materials new characteristics are generally complicated and therefore ... to astonishment when scientists report on new methods which ... they use economically priced starting materials but also do ... framework made of polystyrene This is exactly ...
... Inc. (Nasdaq: MYL ) today announced that it intends to ... senior notes through a reopening of its Senior Notes due 2020, ... as additional notes under an existing indenture under which Mylan issued ... 2020 on May 19, 2010 . The notes to be ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 2Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 3Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 4Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 5Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 6Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 7Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 8Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 9Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 10Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 11Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 12Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 13Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 14Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 15Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 16Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 17Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 18Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 19Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 20Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 21Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 22Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 23Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 24Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 25Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 26Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 27Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 28Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 29Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 30Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 31Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 32Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 33Empa grows 'sea urchin'-shaped structures 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 3
(Date:9/18/2014)... deep in the primitive brainstem has revealed how we ... School of Medicine and the University at Buffalo School ... second "sleep node" identified in the mammalian brain whose ... produce deep sleep. , Published online in August in ... half of all of the brain,s sleep-promoting activity originates ...
(Date:9/18/2014)... Space Station ever starts a "frequent flyers" program, fruit ... the orbiting laboratory has hosted increasing numbers of fruit ... the space station in April, and another is scheduled ... is planned to launch in December. , Fruit flies ... world-- and in space. Model organisms can reveal the ...
(Date:9/18/2014)... their colleagues have built the first smartphone app ... and behavioral trends. In other words, your smartphone ... you don,t -- and how that affects you. ... stress, depression and loneliness to their academic performance, ... for example, to monitor mental health, trigger ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4
... , This news release is available in ... songbirds learn their songs from an adult model, mostly from the ... these songs are copied. Researchers from the Max Planck Institute for ... mechanism that is responsible for the differences in the intensity of ...
... Increasing awareness of biometrics across industries will spur ... adoption of biometrics has been concentrated in the ... for applications such as ATMs, retail points of ... have undergone substantial advancements and are gaining prominence, ...
... scientists are working to determine how neurons are generated, ... like Tuberous Sclerosis Complex (TSC). TSC is a ... in the brain and other vital organs and may ... that may arise from the abnormal generation of neurons. ...
Cached Biology News:Super song learners 2Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 2Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 3Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 4Clemson University study points to possible treatment for brain disorders 2
... Baculovirus Expression System with Gateway™ Technology ... plasmids containing the polyhedrin promoter. The ... baculovirus genome (bacmid DNA) by site-specific ... cells. The recombinant bacmid DNA is ...
Request Info...
...
...
Biology Products: